Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of bevacizumab in locally advanced operable breast cancer
2005-005048-19Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jan 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in breast cancer (2 arms), sponsored by European Institute of Oncology. Primary endpoints: Change in Ki-67 expression and Tumor cell proliferation. Started Jan 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-005048-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005048-19.